Vanderbilt University

iMDx has enrolled its first patient in the GraftAssureDx clinical trial, an observational study designed to validate a kitted transplant rejection monitoring test for kidney transplant recipients.

Leading medical organizations including the American Medical Association, American Academy of Pediatrics, and Infectious Diseases Society of America have been barred from CDC vaccine advisory workgroups.

A comprehensive study of over 692,000 children found that Tamiflu reduces neuropsychiatric events by 50% compared to untreated influenza, contradicting long-standing safety concerns.

A study of 102 older adults found that increasing walking cadence by just 14 steps per minute led to substantial improvements in physical function and frailty outcomes.

UroMems received investigational device exemption approval from the FDA and French ANSM to begin the SOPHIA2 pivotal trial of its UroActive smart implant for treating male stress urinary incontinence.

Neumora Therapeutics has initiated a Phase 1 single-ascending dose/multiple-ascending dose study of NMRA-861, a highly potent and selective positive allosteric modulator of the M4 muscarinic receptor for schizophrenia treatment.

Abvance Therapeutics presented the first human clinical data evaluating fixed-ratio co-administration of insulin and glucagon at mealtime in Type 1 diabetes patients at the 85th ADA Scientific Sessions.

Vanderbilt researchers developed albumin-hitchhiking nanobodies that extend circulation time from 5 minutes to 55 hours and achieve 11% injected dose per gram tumor accumulation.

VU319, an M1 positive allosteric modulator, has demonstrated encouraging results in a Phase 1 clinical trial for Alzheimer's disease and other neurodegenerative conditions.